Article
Expansion of KRAS hotspot mutations reactive T cells from human pancreatic tumors using autologous T cells as the antigen-presenting cells.
Cancer immunology, immunotherapy : CII - 1 May 2023
Wang Sizhen, Zhang Xiaohui, Zou Xuemei, Wen Maorong, Gan Chi, Jiang Xiaochun, Li Min, Shen Rongxi, Zhu Daojun, Yao Anlong, Fang Yu, Fox Bernard A, Hu Hong-Ming, Yu Guangjie, Wang Xinbo
Abstract excerpt
Adoptive cell therapy (ACT) with expanded tumor-infiltrating lymphocytes (TIL) or TCR gene-modified T cells (TCR-T) that recognize mutant KRAS neo-antigens can mediate tumor regression in patients with advanced pancreatic ductal adenocarcinoma (PDAC) (Tran et al in N Engl J Med, 375:2255-2262, 2016; Leidner et al in N Engl J Med, 386:2112-2119, 2022). The mutant KRAS-targeted ACT holds great potential to achieve...
Topics
- Humans
- Proto-Oncogene Proteins p21(ras)
- CD8-Positive T-Lymphocytes
- Lymphocytes, Tumor-Infiltrating
- Antigen-Presenting Cells
- Melanoma
- Pancreatic Neoplasms
- Mutation
- Immunotherapy, Adoptive